\documentclass[10pt,a4paper]{article} % Packages \usepackage{fancyhdr} % For header and footer \usepackage{multicol} % Allows multicols in tables \usepackage{tabularx} % Intelligent column widths \usepackage{tabulary} % Used in header and footer \usepackage{hhline} % Border under tables \usepackage{graphicx} % For images \usepackage{xcolor} % For hex colours %\usepackage[utf8x]{inputenc} % For unicode character support \usepackage[T1]{fontenc} % Without this we get weird character replacements \usepackage{colortbl} % For coloured tables \usepackage{setspace} % For line height \usepackage{lastpage} % Needed for total page number \usepackage{seqsplit} % Splits long words. %\usepackage{opensans} % Can't make this work so far. Shame. Would be lovely. \usepackage[normalem]{ulem} % For underlining links % Most of the following are not required for the majority % of cheat sheets but are needed for some symbol support. \usepackage{amsmath} % Symbols \usepackage{MnSymbol} % Symbols \usepackage{wasysym} % Symbols %\usepackage[english,german,french,spanish,italian]{babel} % Languages % Document Info \author{sam219} \pdfinfo{ /Title (anti-neoplastic-anti-cancer.pdf) /Creator (Cheatography) /Author (sam219) /Subject (Anti-neoplastic/anti-cancer Cheat Sheet) } % Lengths and widths \addtolength{\textwidth}{6cm} \addtolength{\textheight}{-1cm} \addtolength{\hoffset}{-3cm} \addtolength{\voffset}{-2cm} \setlength{\tabcolsep}{0.2cm} % Space between columns \setlength{\headsep}{-12pt} % Reduce space between header and content \setlength{\headheight}{85pt} % If less, LaTeX automatically increases it \renewcommand{\footrulewidth}{0pt} % Remove footer line \renewcommand{\headrulewidth}{0pt} % Remove header line \renewcommand{\seqinsert}{\ifmmode\allowbreak\else\-\fi} % Hyphens in seqsplit % This two commands together give roughly % the right line height in the tables \renewcommand{\arraystretch}{1.3} \onehalfspacing % Commands \newcommand{\SetRowColor}[1]{\noalign{\gdef\RowColorName{#1}}\rowcolor{\RowColorName}} % Shortcut for row colour \newcommand{\mymulticolumn}[3]{\multicolumn{#1}{>{\columncolor{\RowColorName}}#2}{#3}} % For coloured multi-cols \newcolumntype{x}[1]{>{\raggedright}p{#1}} % New column types for ragged-right paragraph columns \newcommand{\tn}{\tabularnewline} % Required as custom column type in use % Font and Colours \definecolor{HeadBackground}{HTML}{333333} \definecolor{FootBackground}{HTML}{666666} \definecolor{TextColor}{HTML}{333333} \definecolor{DarkBackground}{HTML}{D4667F} \definecolor{LightBackground}{HTML}{FCF5F7} \renewcommand{\familydefault}{\sfdefault} \color{TextColor} % Header and Footer \pagestyle{fancy} \fancyhead{} % Set header to blank \fancyfoot{} % Set footer to blank \fancyhead[L]{ \noindent \begin{multicols}{3} \begin{tabulary}{5.8cm}{C} \SetRowColor{DarkBackground} \vspace{-7pt} {\parbox{\dimexpr\textwidth-2\fboxsep\relax}{\noindent \hspace*{-6pt}\includegraphics[width=5.8cm]{/web/www.cheatography.com/public/images/cheatography_logo.pdf}} } \end{tabulary} \columnbreak \begin{tabulary}{11cm}{L} \vspace{-2pt}\large{\bf{\textcolor{DarkBackground}{\textrm{Anti-neoplastic/anti-cancer Cheat Sheet}}}} \\ \normalsize{by \textcolor{DarkBackground}{sam219} via \textcolor{DarkBackground}{\uline{cheatography.com/201893/cs/45447/}}} \end{tabulary} \end{multicols}} \fancyfoot[L]{ \footnotesize \noindent \begin{multicols}{3} \begin{tabulary}{5.8cm}{LL} \SetRowColor{FootBackground} \mymulticolumn{2}{p{5.377cm}}{\bf\textcolor{white}{Cheatographer}} \\ \vspace{-2pt}sam219 \\ \uline{cheatography.com/sam219} \\ \end{tabulary} \vfill \columnbreak \begin{tabulary}{5.8cm}{L} \SetRowColor{FootBackground} \mymulticolumn{1}{p{5.377cm}}{\bf\textcolor{white}{Cheat Sheet}} \\ \vspace{-2pt}Not Yet Published.\\ Updated 14th January, 2025.\\ Page {\thepage} of \pageref{LastPage}. \end{tabulary} \vfill \columnbreak \begin{tabulary}{5.8cm}{L} \SetRowColor{FootBackground} \mymulticolumn{1}{p{5.377cm}}{\bf\textcolor{white}{Sponsor}} \\ \SetRowColor{white} \vspace{-5pt} %\includegraphics[width=48px,height=48px]{dave.jpeg} Measure your website readability!\\ www.readability-score.com \end{tabulary} \end{multicols}} \begin{document} \raggedright \raggedcolumns % Set font size to small. Switch to any value % from this page to resize cheat sheet text: % www.emerson.emory.edu/services/latex/latex_169.html \footnotesize % Small font. \begin{multicols*}{3} \begin{tabularx}{5.377cm}{x{1.87657 cm} x{1.8308 cm} x{0.86963 cm} } \SetRowColor{DarkBackground} \mymulticolumn{3}{x{5.377cm}}{\bf\textcolor{white}{Alkylating agents}} \tn % Row 0 \SetRowColor{LightBackground} Sulfur mustard\{\{ac\}\} & Nitrogen mustard/ 1)Meclorethamine\{\{ac\}\} & Nitrosurea\{\{ac\}\} \tn % Row Count 3 (+ 3) % Row 1 \SetRowColor{white} & Given IV. & Streptoazocin\{\{ac\}\} \tn % Row Count 6 (+ 3) % Row 2 \SetRowColor{LightBackground} is converted into {\bf{episulfonuim ion}} attacked by nucleophile from cells and becomes alkylated biopolymer. & Becomes the unstable {\bf{aziridinuim ion}} and then gives alkylated biopolymer. & \tn % Row Count 13 (+ 7) % Row 3 \SetRowColor{white} & 2) Chlorambucil \{\{ac\}\} & \tn % Row Count 15 (+ 2) % Row 4 \SetRowColor{LightBackground} & Relatively stable; given oral. & \tn % Row Count 17 (+ 2) % Row 5 \SetRowColor{white} & Least toxic, long-acting. & \tn % Row Count 19 (+ 2) % Row 6 \SetRowColor{LightBackground} & 3) Cyclophosamide\{\{ac\}\} & \tn % Row Count 21 (+ 2) % Row 7 \SetRowColor{white} & Active orally and parenterally. & \tn % Row Count 23 (+ 2) \hhline{>{\arrayrulecolor{DarkBackground}}---} \SetRowColor{LightBackground} \mymulticolumn{3}{x{5.377cm}}{Both sulfur and nitrogen mustard are converted into unstable 3-membered (onium) intermediates that they act by.} \tn \hhline{>{\arrayrulecolor{DarkBackground}}---} \end{tabularx} \par\addvspace{1.3em} \begin{tabularx}{5.377cm}{x{2.4885 cm} x{2.4885 cm} } \SetRowColor{DarkBackground} \mymulticolumn{2}{x{5.377cm}}{\bf\textcolor{white}{Plant products}} \tn % Row 0 \SetRowColor{LightBackground} Vinca alkaloids\{\{ac\}\} & Ixabepilone \{\{ac\}\} \tn % Row Count 2 (+ 2) % Row 1 \SetRowColor{white} Include vincristine, vinblastine, vinrosidine, vinleurosine & semisynthetic amide analogue of the spindle poison, Epothilone B. \tn % Row Count 6 (+ 4) % Row 2 \SetRowColor{LightBackground} 1) Paclitaxel (taxol) & Has lactam in its structure providing increased {\emph{invivo}} stability. \tn % Row Count 10 (+ 4) % Row 3 \SetRowColor{white} MOA: spindle poison inhibiting mitosis. & Uses: Metastatic breast cancer \tn % Row Count 12 (+ 2) % Row 4 \SetRowColor{LightBackground} \mymulticolumn{2}{x{5.377cm}}{Uses: ttt of breast, ovarian \& {\bf{aids-related kaposi sarcoma}}.} \tn % Row Count 14 (+ 2) \hhline{>{\arrayrulecolor{DarkBackground}}--} \end{tabularx} \par\addvspace{1.3em} \begin{tabularx}{5.377cm}{x{2.4885 cm} x{2.4885 cm} } \SetRowColor{DarkBackground} \mymulticolumn{2}{x{5.377cm}}{\bf\textcolor{white}{Signal transduction (PK) inhibitors}} \tn % Row 0 \SetRowColor{LightBackground} Imatinib mesylate\{\{ac\}\} & Sorafenib tosylate\{\{ac\}\} \tn % Row Count 2 (+ 2) % Row 1 \SetRowColor{white} MOA: Competitive inhibition of TK-{}-\textgreater{} inducing {\bf{apoptosis or non-dividing cells.}} & MOA: Broad spectrum kinase inhibitor \tn % Row Count 7 (+ 5) % Row 2 \SetRowColor{LightBackground} Uses: CML, GIST, acute lymphoblastic leukemia (+ve philadelphia chromosomes) & Uses: renal cell carcinoma and colon cancer \tn % Row Count 11 (+ 4) % Row 3 \SetRowColor{white} SE: thrombocytopenis, skin rash, N/V, pulmonary edema. & SE: Skin rash, HTN, fatigue, increased risk of bleeding \& wound healing time. \tn % Row Count 15 (+ 4) \hhline{>{\arrayrulecolor{DarkBackground}}--} \SetRowColor{LightBackground} \mymulticolumn{2}{x{5.377cm}}{Advantage: Orally administered, better patient tolerability. \newline Disadvantage: Cardiotoxicity \newline \newline {\bf{Resistance to tyrosine kinase forms}}: \newline - Altering amino a' to stop binding \newline - Increasing kinase levels \newline - Drug is substrate to efflux transporter, BCRP.} \tn \hhline{>{\arrayrulecolor{DarkBackground}}--} \end{tabularx} \par\addvspace{1.3em} \begin{tabularx}{5.377cm}{x{1.55618 cm} x{1.51041 cm} x{1.51041 cm} } \SetRowColor{DarkBackground} \mymulticolumn{3}{x{5.377cm}}{\bf\textcolor{white}{Anti-metabolites}} \tn % Row 0 \SetRowColor{LightBackground} Pyrimidine \seqsplit{antimetabolites} & Purine \seqsplit{antimetabolites} & Folic a' \seqsplit{antimetabolites} \tn % Row Count 2 (+ 2) % Row 1 \SetRowColor{white} 1) 5-FU\{\{ac\}\} & 1) 6-MP\{\{ac\}\} & 1) Methotrexate\{\{ac\}\} \tn % Row Count 4 (+ 2) % Row 2 \SetRowColor{LightBackground} MOA: thymidylate synthase inhibitor or incorporated into RNA \& DNA. & Is {\emph{invivo}} converted into \seqsplit{6-thionosinate}. & MOA: \seqsplit{dihydrofolate} reductase inhibitor \tn % Row Count 10 (+ 6) % Row 3 \SetRowColor{white} 2) Uracil mustard & MOA: inhibits the \seqsplit{rate-limiting} step during purine synthesis. & Uses: remission in leukaemia and breast cancer management. \tn % Row Count 15 (+ 5) % Row 4 \SetRowColor{LightBackground} Alkylating agent. & Uses: & \tn % Row Count 17 (+ 2) % Row 5 \SetRowColor{white} MOA: Damages DNA that in take in uracil. & - with methotraxate for lymphocytic leukemia. & \tn % Row Count 21 (+ 4) % Row 6 \SetRowColor{LightBackground} Uses: Non-hodgkins lymphoma & - \seqsplit{Immunosuppressive} for UC, psoriatic arthirits, systemic lopus \seqsplit{erythromatosis}. & \tn % Row Count 28 (+ 7) % Row 7 \SetRowColor{white} & Allopurinol potentiates its effect by inhibiting its metabolism. & \tn % Row Count 33 (+ 5) \hhline{>{\arrayrulecolor{DarkBackground}}---} \end{tabularx} \par\addvspace{1.3em} \begin{tabularx}{5.377cm}{x{2.4885 cm} x{2.4885 cm} } \SetRowColor{DarkBackground} \mymulticolumn{2}{x{5.377cm}}{\bf\textcolor{white}{Miscellaneous compounds}} \tn % Row 0 \SetRowColor{LightBackground} Platinum complexes\{\{ac\}\} & Synthetic retinoid analog\{\{ac\}\} \tn % Row Count 2 (+ 2) % Row 1 \SetRowColor{white} 1) Cisplatin & 1) Bexarotene \tn % Row Count 3 (+ 1) % Row 2 \SetRowColor{LightBackground} MOA: Cross-links DNA causing DNA conformational changes. & MOA: binds to activated retinoid X receptors in skin. \tn % Row Count 6 (+ 3) % Row 3 \SetRowColor{white} Uses: {\bf{with bleomycin \& vinblastine}} for metastatic testicular tumors. & Use: cutaneous T-cell lymphoma \tn % Row Count 10 (+ 4) % Row 4 \SetRowColor{LightBackground} \mymulticolumn{2}{x{5.377cm}}{2) Carboplatin} \tn % Row Count 11 (+ 1) \hhline{>{\arrayrulecolor{DarkBackground}}--} \end{tabularx} \par\addvspace{1.3em} \begin{tabularx}{5.377cm}{x{1.46464 cm} x{1.55618 cm} x{1.55618 cm} } \SetRowColor{DarkBackground} \mymulticolumn{3}{x{5.377cm}}{\bf\textcolor{white}{Immunotherapy/monoclonal antibodies}} \tn % Row 0 \SetRowColor{LightBackground} **Block\{\{ac\}\} & **Flag\{\{ac\}\} & **Deliver\{\{ac\}\} \tn % Row Count 2 (+ 2) % Row 1 \SetRowColor{white} 1) Trastuzumab & 1) Rituximab & 1) Brentuximab vedotin \tn % Row Count 4 (+ 2) % Row 2 \SetRowColor{LightBackground} Blocks HER-2 receptors to stop growth. & chimeric (hybrid) monoclonal antibody. & Delivers chemotherapy drugs inside tumor cells. \tn % Row Count 8 (+ 4) % Row 3 \SetRowColor{white} 2) Bevacizumab & Flag malignant B lymphocytes with CD20 receptor for the immune cells. & \tn % Row Count 14 (+ 6) % Row 4 \SetRowColor{LightBackground} Blocks VEGF-{}-\textgreater{} no new blood vessels. & Use: Non-Hodgkins B-cell lymphoma. & \tn % Row Count 17 (+ 3) \hhline{>{\arrayrulecolor{DarkBackground}}---} \SetRowColor{LightBackground} \mymulticolumn{3}{x{5.377cm}}{MOA: targeted therapy by {\bf{selective binding on receptor to-{}-}}**} \tn \hhline{>{\arrayrulecolor{DarkBackground}}---} \end{tabularx} \par\addvspace{1.3em} \begin{tabularx}{5.377cm}{x{2.4885 cm} x{2.4885 cm} } \SetRowColor{DarkBackground} \mymulticolumn{2}{x{5.377cm}}{\bf\textcolor{white}{Antibiotics}} \tn % Row 0 \SetRowColor{LightBackground} Anthracyclines\{\{ac\}\} & Actinomycin\{\{ac\}\} \tn % Row Count 1 (+ 1) % Row 1 \SetRowColor{white} 1) Danorubicin HCl & 1) Bleomycin \tn % Row Count 2 (+ 1) % Row 2 \SetRowColor{LightBackground} MOA: intercalates into DNA causing indirect inhibition of topoisomerase II-{}-\textgreater{} decreased RNA \& DNA synthesis. & Has multiple heterocyclic rings and cytotoxic glycosides. \tn % Row Count 8 (+ 6) % Row 3 \SetRowColor{white} SE: Cardiotoxicity, release of hydroxyl and superoxide radicals. & MOA: Fragmentation of DNA. \tn % Row Count 12 (+ 4) % Row 4 \SetRowColor{LightBackground} 2) Doxorubicin HCl & 2) Mitomycin C \tn % Row Count 13 (+ 1) % Row 5 \SetRowColor{white} Uses: Acute leukaemia, Hodgkins's disease & 3 anti-cancer functional gps: Quinone + Aziridine + Carbamate. \tn % Row Count 17 (+ 4) % Row 6 \SetRowColor{LightBackground} & MOA: cross-links double helical DNA \tn % Row Count 19 (+ 2) % Row 7 \SetRowColor{white} & Unreactive in natural state-{}-reduction-{}-\textgreater{} Indol-hydroquinone (bifunctional alkylating agent) \tn % Row Count 24 (+ 5) \hhline{>{\arrayrulecolor{DarkBackground}}--} \end{tabularx} \par\addvspace{1.3em} \begin{tabularx}{5.377cm}{x{1.55618 cm} x{1.51041 cm} x{1.51041 cm} } \SetRowColor{DarkBackground} \mymulticolumn{3}{x{5.377cm}}{\bf\textcolor{white}{Hormones}} \tn % Row 0 \SetRowColor{LightBackground} Testolactone\{\{ac\}\} & Tamoxifen\{\{ac\}\} & Letrozole\{\{ac\}\} \tn % Row Count 2 (+ 2) % Row 1 \SetRowColor{white} MOA: Aromatase inhibitor stopping estrogen synthesis from \seqsplit{testosterone.} & \seqsplit{Non-steroidal} agent with \seqsplit{anti-estrogen} properties. & MOA: Aromatase inhibitor \tn % Row Count 8 (+ 6) % Row 2 \SetRowColor{LightBackground} Uses: Breast cancer in \seqsplit{post-menopausal} women. & MOA: binds to estorgen receptors resulting in decreased DNA \seqsplit{transcription}. & Uses: locally advanced or metastatic breast cancer. \tn % Row Count 14 (+ 6) % Row 3 \SetRowColor{white} & Uses: breast cancer in \seqsplit{post-menopausal} women. & \tn % Row Count 18 (+ 4) \hhline{>{\arrayrulecolor{DarkBackground}}---} \end{tabularx} \par\addvspace{1.3em} % That's all folks \end{multicols*} \end{document}